Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
Date:3/3/2010

ent regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. Compensation of our executives is based in part on the performance of our business based on these non-GAAP measures. In addition, we believe that the use of these non-GAAP measures enhances the ability of investors to compare our results both from period to period and with those of other companies.  Investors should note that adjusted net income/(loss) and adjusted net income/(loss) per diluted share, as used by Jazz Pharmaceuticals, may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by our competitors and other companies.

SOURCE Jazz Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.jazzpharmaceuticals.com

'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
(Date:7/10/2014)... 10, 2014 CVS Caremark Corporation (NYSE: ... approved a quarterly dividend of $0.275 (27.5 cents) per share ... August 1, 2014, to holders of record on July 21, ... Caremark is dedicated to helping people on their path to ... the United States . Through the company,s more ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... 20, 2012  NxStage Medical, Inc. (Nasdaq: NXTM ... announced plans to release its financial results for the ... on Wednesday, February 29, 2012  before the opening of ... ) NxStage will also host a conference ...
... 2012  INVO Bioscience, Inc. (OTC BB: IVOB), a medical ... with infertility, today announced that the National Health Surveillance ... INVOcell for use as a Class II device. This ... of infertile couples in Brazil and marks a major ...
Cached Medicine Technology:NxStage® to Report Fourth Quarter and Full Year 2011 Financial Results 2INVO Bioscience Announces Approval of INVOcell by Brazil's ANVISA 2INVO Bioscience Announces Approval of INVOcell by Brazil's ANVISA 3
(Date:7/12/2014)... SATURDAY, July 12, 2014 (HealthDay News) -- If you make ... contends. In one experiment, 56 adults were led on ... an exercise walk or a scenic walk. The participants were ... it was an exercise outing ate 35 percent more chocolate ... a scenic walk. In another experiment, 46 adults were ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 Using ... so one of two inventors from Ashland, Va., decided ... do this. "This inspired us to conceive of our ... of the patent-pending KIDNEY KOVER, which provides an inconspicuous ... It avoids embarrassment, as well as promotes comfort and ...
(Date:7/12/2014)... 2014 “Critical Care Therapeutics in ... Late-Stage Four-Factor PCCs and Recombinant Products to Drive ... care market in the US, UK, France, Germany, ... an estimation of market size for 2013, along ... care indications that are being treated using the ...
(Date:7/12/2014)... article released by Seattle's well known plastic surgeon, Dr. Bryan ... cosmetic surgical procedures in summer months . , As ... enliven the rainy Pacific Northwest, many people are turning their ... out as much during the winter as they had planned. ... eager to look their best for their summer vacations, and ...
(Date:7/12/2014)... West Palm Beach, FL (PRWEB) July 12, 2014 ... wide variety of high-quality peptides that are used solely ... online. To honor two successful years in business, Maxim ... Performance LLC, has just launched a new and updated ... addition, the research blog section has been updated with ...
Breaking Medicine News(10 mins):Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2
... Macmillan Cancer Support of UK has taken a strong campaign ... that in Scotland people spent// an average of ?636 on ... in Wales. ,The demand of the charity is ... ,"These regional variations are shocking and grossly unfair - cancer ...
... to heart abnormalities, is apparently safe to use in ... yesterday//. The researchers said that they found no ... their pregnancies fearing that the drug could affect their ... studied 119 women treated with Seroxat for six years ...
... suffering, a tuberculosis (TB) patient in Madhya Pradesh has requested Indian ... life and that of his four minor children. ... late 40s, is suffering from TB and has long been dependent ... of TB a few years ago. ,He has now ...
... chemical compound found in cannabis, also known as hashish ... after testing it on rats //. ,Yehoshua ... Israel, has created a synthetic version of a minor ... help in lowering blood pressure, reported science portal The ...
... a common school system in the country, educationists Sunday ... primary education //system and remove disparities among students. ... system in the country so that all students get ... said Madhu Prasad, educationist and a professor in Delhi ...
... Administration borrowed data from the 2004 National Survey on ... persons, 12 years of age or older, made ... to the survey. Meanwhile, an estimated 2.1 million Americans ... cocaine abuse. ,The statistics revealed the following ...
Cached Medicine News:
... eliminate false signals and contamination caused ... Promega Barrier Tips offer performance and ... acids (PCR(a)), radioactive isotopes, tissue culture ... specimens. , ,Promega Barrier Tips are ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
... AvantGard Low Binding 0.5l - 10l Eppendorf ... binding technology that significantly reduces the amount of ... other filter tips are advertised as low retention, ... adhering to the pipet tip. However, AvantGard also ...
10 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 2, 5 and 10 L pipettes....
Medicine Products: